Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Monk

Showing results (141-150 of 738) with videos related to

Pageof 74
Sort By:
Gynecologic Oncology|June 27, 2006
Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcomaDevansu Tewari, Bahman Saffari, Carol Cowan, et al.
Gynecologic Oncology|April 26, 2002
Primary invasive vaginal cancer in the setting of the Mayer-Rokitansky-Kuster-Hauser syndromeDevansu S Tewari, Michael T McHale, Jeffrey V Kuo, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 25, 2020
CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter studyJyoti Mayadev, Ana T Nunes, Mary Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2007
An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapyPing-Yu Liu, David S Alberts, Bradley J Monk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 21, 2007
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group StudyRobert A Burger, Michael W Sill, Bradley J Monk, et al.
Gynecologic Oncology|March 25, 2014
Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: an exploratory study of the gynecologic oncology groupKrishnansu S Tewari, James J Java, Troy A Gatcliffe, et al.
Gynecologic Oncology Research and Practice|May 28, 2016
Protein profiling of ovarian cancers by immunohistochemistry to identify potential target pathwaysCassandra D Foss, Heather J Dalton, Bradley J Monk, et al.
Journal of Lower Genital Tract Disease|October 6, 2007
Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening programNeal M Lonky, Mark I Hunter, Mashod Sadeghi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2015
Psychosocial telephone counseling for survivors of cervical cancer: results of a randomized biobehavioral trialLari Wenzel, Kathryn Osann, Susie Hsieh, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 28, 2023
Evolving treatment paradigms in metastatic or recurrent low-grade endometrial cancer: When is hormonal-based therapy the preferred option?Haider Mahdi, Isabelle Ray-Coquard, Domenica Lorusso, et al.
Pageof 74

Showing results (141-150 of 738) with videos related to

Sort By:
Pageof 74
Gynecologic Oncology|June 27, 2006
Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcomaDevansu Tewari, Bahman Saffari, Carol Cowan, et al.
Gynecologic Oncology|April 26, 2002
Primary invasive vaginal cancer in the setting of the Mayer-Rokitansky-Kuster-Hauser syndromeDevansu S Tewari, Michael T McHale, Jeffrey V Kuo, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 25, 2020
CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter studyJyoti Mayadev, Ana T Nunes, Mary Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2007
An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapyPing-Yu Liu, David S Alberts, Bradley J Monk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 21, 2007
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group StudyRobert A Burger, Michael W Sill, Bradley J Monk, et al.
Gynecologic Oncology|March 25, 2014
Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: an exploratory study of the gynecologic oncology groupKrishnansu S Tewari, James J Java, Troy A Gatcliffe, et al.
Gynecologic Oncology Research and Practice|May 28, 2016
Protein profiling of ovarian cancers by immunohistochemistry to identify potential target pathwaysCassandra D Foss, Heather J Dalton, Bradley J Monk, et al.
Journal of Lower Genital Tract Disease|October 6, 2007
Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening programNeal M Lonky, Mark I Hunter, Mashod Sadeghi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2015
Psychosocial telephone counseling for survivors of cervical cancer: results of a randomized biobehavioral trialLari Wenzel, Kathryn Osann, Susie Hsieh, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 28, 2023
Evolving treatment paradigms in metastatic or recurrent low-grade endometrial cancer: When is hormonal-based therapy the preferred option?Haider Mahdi, Isabelle Ray-Coquard, Domenica Lorusso, et al.
Pageof 74